MultiCare and Samaritan merge, plan $700 million investment in facilities and tech
MultiCare and Samaritan have merged, with MultiCare set to invest $700 million in Samaritan’s facilities and technology. Senior healthcare leaders should note the scale of planned upgrades and the regulatory approval involved. Watch for how the investment shapes regional care delivery.
Servier’s $1.55 billion muscular dystrophy drug fails key clinical trial
Servier reported a setback for its $1.55 billion drug in a major muscular dystrophy trial. This raises questions for pharma leaders about risk in rare disease pipelines. Watch for how Servier and peers adjust rare disease strategies.
RiverStone International enters ILS market with US$1.6bn QBE portfolio transfer
RiverStone International has completed two major loss portfolio transfer deals, including its first in the insurance-linked securities market. The US$1.6 billion QBE transaction expands RiverStone’s reach in legacy risk transfer. Insurers and reinsurers may see new options for managing legacy exposures.
Barclays increases client reviews to track flood risk as UK insurance access tightens
Barclays has intensified its client review process to monitor flood exposure, citing rising climate risks and insurance challenges. This matters for banks and insurers as UK firms struggle to secure cover and adjust capital allocation. Watch for regulatory scrutiny and insurance market shifts.
Fiserv seeks asset sales and doubles savings target to $1 billion
Fiserv is in talks with potential buyers for some of its assets and has raised its savings goal to $1 billion, according to its CEO. Senior leaders in finance and payments should watch for possible shifts in market structure and competitive positioning. Asset sales may affect future partnerships or services.
FTC and eight states sue Toast over hidden fees and contract practices
The FTC and eight states have sued Toast Inc., alleging hidden fees, unauthorised charges and complex cancellations for restaurant clients. The case tests how consumer protection laws apply to B2B software providers. Regulated firms should review their own contract and fee disclosures.
Democrats gain Senate control, raising uncertainty for Trump-era health policies
Democrats have secured Senate control, giving them the ability to challenge Trump-era health care actions. This shift could affect regulatory priorities for healthcare and pharma leaders. Watch for policy changes that may alter compliance or market strategies.
US clinics bill urgent care as ER, raising costs for patients
STAT reports that some US clinics are billing urgent care visits as emergency room care, leading to higher charges for patients. This practice affects affordability and raises questions for insurers and providers. Watch for policy changes or insurer responses.
FDIC eases capital status for Old Glory Bank after acquisition fails
The FDIC reclassified Old Glory Bank as 'adequately capitalized' last week, reversing a tougher stance from August. This shift follows the collapse of a special-purpose acquisition. Bank leaders should note the regulatory adjustment and its timing.
Supermarkets in seven countries face cyber-attacks on refrigeration systems
Supermarket chains in seven European countries reported cyber-attacks that raised fridge and freezer temperatures to 50C, echoing a recent French incident. For banks, insurers and retailers, this shows a growing risk to critical supply chains and operational technology. Firms should review their cyber defences urgently.
Palantir’s US commercial revenue overtakes government business at $984m
Palantir’s US commercial revenue rose 148% to $984m, surpassing US government sales for the first time. The shift signals growing demand from regulated industries for AI-driven software. Executives should watch for how rivals and regulators respond to Palantir’s expansion.
AIG buys Everest Chile and completes Everest Colombia deal to grow in Latin America
AIG will acquire Everest's insurance subsidiary in Chile and has completed its purchase of Everest Colombia, according to both firms. The move expands AIG's reach in Latin America's growing corporate insurance sector. Leaders should watch for regulatory approval and integration steps.
Revolut gains New Zealand bank licence to challenge established lenders
Revolut has secured registration as New Zealand’s 27th bank, according to the Reserve Bank. This approval allows the fintech to offer savings and credit products in a market dominated by Australia’s Big Four. Senior leaders should watch for increased competition and regulatory scrutiny.
FDA approves generic HIV prevention shot for global access
The FDA has approved a generic HIV prevention shot, aiming to expand access in lower-income countries. This move could affect drug pricing and public health policy for pharma and healthcare leaders. Watch for changes in procurement and global health strategy.
Publicis completes $2.2 billion LiveRamp deal, keeps platform independent
Publicis has finalised its $2.2 billion acquisition of LiveRamp, keeping the data platform independent under CEO Scott Howe. The FTC imposed five years of neutrality requirements. Brand leaders should watch how this affects data control and agency relationships.
Four drugmakers accused of paying millions to Russian middlemen for drug supply
STAT reports that four major drugmakers allegedly paid tens of millions to middlemen to supply lifesaving drugs to Russian government entities. This raises compliance and reputational risks for pharma leaders. Firms may need to review third-party controls and due diligence.
Amazon’s AI spend drives free cash flow to minus $42.4bn as AWS revenue grows 39%
Amazon’s free cash flow dropped to minus $42.4bn as AI spending surged, with AWS revenue up 39% to $46bn. This sharp rise in investment and cloud growth signals major shifts for regulated-industry leaders. Watch for Amazon’s plans to expand AI chip sales in 2027.
French MPs back €0.055 per GB data tax, raising €10bn risk for tech firms
France’s National Assembly passed a €0.055 per gigabyte data tax, aiming to raise €10bn a year. The move targets content providers and could affect costs for banks, insurers and healthcare firms using digital platforms. The Senate and government may still block it.
US Republicans join Democrats in targeting CVS over drug prices
Republicans have joined Democrats in criticising pharmacy groups like CVS for high drug prices, according to Politico. This signals growing bipartisan scrutiny of pharmacy benefit managers. Senior healthcare and pharma leaders should expect more regulatory attention.
Condé Nast faces $35 million Q4 ad shortfall amid executive exits and weak event revenue
Condé Nast expects its Q4 ad revenue to fall over $35 million short, as reported by Adweek. The gap comes after multiple leadership departures and missed event targets. Senior marketing and commercial leaders should watch for further strategy shifts or cost cuts.